Stratasys Unveils New Software and Materials to Enhance Additive Manufacturing
Stratasys unveiled a slate of new application-driven software capabilities, materials, and platform enhancements designed to empower manufacturers to push additive manufacturing beyond concept models and into production parts faster than ever. Stratasys will enable organizations to move the production of more parts and tools from traditional methods into additive workflows, by streamlining design and ease of use, improving reliability, and expanding materials and platform capabilities. This approach will dramatically increase speed and performance while reducing costs. The J850 Core printer expands the PolyJet(TM) technology lineup with a lower-cost system built for engineering teams focused on functional prototyping. It gives customers access to PolyJet performance and materials without paying for full-color capabilities. These advancements hit the sweet spot between capability and cost for teams that want speed and reliability at a more practical price point. The system is planned to be open for booking by the end of April.Stratasys and Shin-Etsu are introducing P3 MED Silicone 25A, the first biocompatible true silicone for 3D printing patient-specific medical devices and low-volume production parts, available exclusively on Origin printers. Fully certified to ISO 10993 standards, the material delivers authentic silicone properties such as elasticity, durability, and resistance to heat, chemicals, and aging. This combination overcomes many challenges traditionally associated with 3D printing true silicone.
Trade with 70% Backtested Accuracy
Analyst Views on SSYS
About SSYS
About the author

- Revenue Beat: Stratasys reported Q1 revenue of $132.7 million, surpassing the consensus estimate of $131.8 million, demonstrating resilience in the 3D printing market despite ongoing profitability challenges.
- Widening Losses: The net loss deepened to $23.8 million, or $0.28 per share, compared to a loss of $13.1 million a year earlier, reflecting the impact of rising costs and a cautious market environment.
- Margin Pressure: While revenue remained steady, gross margin and operating performance weakened, with EBITDA dropping from $8.2 million last year to $2.0 million, indicating persistent margin pressures due to tariffs and foreign exchange fluctuations.
- Optimistic Outlook: Stratasys reaffirmed its full-year revenue guidance of $565 million to $575 million, expecting gradual improvement, particularly driven by demand in high-performance applications like defense, which could bolster future growth.
- Earnings Highlights: Stratasys reported a Q1 non-GAAP EPS of -$0.01, beating expectations by $0.01, with revenue of $132.7 million, a 2.4% year-over-year decline, yet surpassing forecasts by $0.88 million, indicating resilience amid challenges.
- Adjusted EBITDA Decline: The adjusted EBITDA stood at $2.0 million, significantly down from $8.2 million in the prior year, primarily due to foreign exchange impacts and tariffs, reflecting challenges in cost management for the company.
- Cash Flow and Debt Position: The company reported positive operating cash flow of $2.4 million, although lower than $4.5 million in the previous year, while holding $237.8 million in cash and short-term deposits with no debt, showcasing financial stability.
- 2026 Outlook: Stratasys reiterated its revenue target for 2026 at $565 million to $575 million, with expected non-GAAP gross margins of 46.7% to 47.1%, despite facing approximately $7 million in adverse impacts from tariffs and foreign exchange rates, demonstrating confidence in future growth prospects.
- Earnings Announcement: Stratasys (SSYS) is set to release its Q1 earnings on May 7 before market open, with consensus EPS estimate at -$0.02, reflecting an 88.9% year-over-year improvement, while revenue is projected at $131.82 million, down 3.1% year-over-year.
- Historical Performance: Over the past two years, Stratasys has beaten EPS estimates 75% of the time and revenue estimates 88% of the time, indicating a degree of financial stability in its performance metrics.
- Estimate Revision Trends: In the last three months, there have been no upward revisions to EPS estimates and three downward revisions, while revenue estimates saw one upward revision with no downward adjustments, suggesting a cautious market outlook on the company's future performance.
- Industry Outlook Analysis: Despite recent earnings reports showing declines in revenue and margins, there remains optimism around Stratasys's prospects in the aerospace and defense sectors, with a revenue target of $565 million to $575 million by 2026, highlighting the company's strategic focus on expanding manufacturing and partnerships.
- Stratasys Performance Decline: Stratasys, with a market cap of $714.4 million, has experienced a 6.3% annual sales decline over the past two years, facing significant end-market challenges that raise doubts about its long-term business viability due to ongoing operating margin losses.
- 10x Genomics Growth Struggles: 10x Genomics, valued at $2.94 billion, reported only 1.9% annual revenue growth in the last two years, failing to meet healthcare sector standards, and its smaller revenue base has hindered its ability to achieve economies of scale, resulting in negative returns on capital.
- Atlas Energy Solutions Financial Pressure: Atlas Energy Solutions, with a market cap of $1.41 billion, has seen expenses increase as a percentage of revenue over the past five years, with its EBITDA margin falling by 20.8 percentage points, raising concerns about its ability to achieve sustainable long-term growth due to cash burn.
- Small-Cap Investment Risks: While small-cap stocks offer savvy investors the chance to act before broader market recognition, they also carry increased downside risks due to limited Wall Street coverage and lack of scale compared to larger competitors, necessitating careful selection by investors.

- Market Rebound: Stocks surged in the morning session, with the S&P 500 jumping over 1% as stabilizing oil prices and President Trump's signals to de-escalate military conflict in Iran eased investor concerns about prolonged conflict, thereby boosting market sentiment.
- Stock Performance: Aerospace company Woodward (NASDAQ:WWD) and electronic components firm Vishay Precision (NYSE:VPG) both rose by 3.4%, while renewable energy company Nextpower (NASDAQ:NXT) increased by 3.3%, indicating a positive market response that may present buying opportunities for investors.
- Stratasys Volatility: Stratasys (NASDAQ:SSYS) shares rose by 3.6%, despite experiencing 21 moves greater than 5% over the past year, suggesting that today's increase reflects a meaningful market reaction to Trump's news without fundamentally altering perceptions of the business.
- Long-term Performance: Stratasys is down 15.5% year-to-date, trading at $7.61 per share, which is 38.8% below its 52-week high of $12.44, indicating significant challenges for long-term investors who would see their $1,000 investment from five years ago reduced to only $293.82.
- Market First Certification: Stratasys's TrueDent® resins become the first high-esthetic, monolithic 3D-printed denture solution to achieve CE Class IIa certification in Europe, marking a significant milestone in a market exceeding $2 billion, which is expected to drive the company's market share growth in digital dentures.
- Expanded Indications: The new certification allows TrueDent® resins to be used for intraoral removables for over 30 days, as well as crowns and bridges, enabling dental laboratories to handle a wider range of restorative cases through a single integrated digital workflow, thereby enhancing production efficiency and customer satisfaction.
- Growing Market Demand: According to a 2024 iData report, the demand for denture solutions in Europe is projected to grow from $2.19 billion in 2023 to $2.45 billion by 2028, indicating significant market potential, and Stratasys's certification will further facilitate its business expansion in this sector.
- Enhanced Customer Confidence: The CE Class IIa certification reflects the regulatory standards expected for restorative dental materials, boosting confidence among dental laboratories and clinicians, supporting broader market adoption, and ensuring the biocompatibility and clinical safety of TrueDent resins.









